Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

This programme is designed to advance next-generation vaccines, therapeutics, and other tools to combat Covid-19. The therapeutic, dubbed S-892216, leverages protease inhibitor technology to block ...

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Covid-19 is now ubiquitous – but hospitalisations ... we still need better therapeutics and vaccines, for some people at least in the future." For essential climate news and hopeful developments ...

Among adults in Ravensburg, Germany, financial incentives for COVID-19 vaccination did not result in significant changes to vaccine uptake and may have inadvertently lowered community vaccination ...

A new way to neutralize coronavirus and other membrane-surrounded viruses has been discovered by researchers from the Swedish ...

The rate of antiviral prescriptions was 67% lower in pregnant than in nonpregnant women, including those with one or more high-risk underlying conditions.

Project NextGen is a $5 billion initiative aimed at developing the next generation of vaccines and therapeutics for COVID-19. Disclaimer: This is an AI-generated summary of a press release ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism. Click for my ARCT stock update.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...